CoChat

Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study

Open access
Agnelli, Giancarlo, Becattini, Cecilia, Bauersachs, Rupert, Brenner, Benjamin, Campanini, Mauro, Cohen, Alexander, Connors, Jean, Fontanella, Andrea, Gussoni, Gualberto, Huisman, Menno, Lambert, Catherine, Meyer, Guy, Muñoz, Andres, Abreu de Sousa, Joaquim, Torbicki, Adam, Verso, Melina, Vescovo, Giorgio, for the Caravaggio Study Investigators · 2018 · Thrombosis and Haemostasis
Cited by 146

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

International and national guidelines recommend low-molecular-weight heparin for the treatment of venous thromboembolism (VTE) in patients with cancer. The aim of the Caravaggio study is to assess whether oral apixaban is non-inferior to subcutaneous dalteparin for the treatment of acute proximal deep vein thrombosis and/or pulmonary embolism in patients with cancer. The study is an investigator-initiated, multi-national, prospective, randomized, open-label with blind end-point evaluation (PROBE), non-inferiority clinical trial (NCT03045406). Consecutive patients are randomized to receive oral apixaban or subcutaneous dalteparin for 6 months. Apixaban is given at a dose of 10 mg twice daily for the first 7 days and then 5 mg twice daily; dalteparin is given at a dose of 200 IU/kg for the first month and then 150 IU/kg once daily. The primary outcome of the study is objectively confirmed recurrent VTE as assessed by a central independent adjudication committee unaware of study treatment allocation. The primary safety outcome is major bleeding defined according to the guidelines of the International Society of Thrombosis and Haemostasis. Assuming a 6-month incidence of the primary outcome of 7% with dalteparin and an upper limit of the two-sided 95% confidence interval of the hazard ratio below the pre-specified margin of 2.00, 1,168 patients will be randomized considering an up to 20% loss in total patient-years (β = 80%; α one-sided = 0.025). The Caravaggio study has the potential, along with other recently performed or on-going studies, to make less cumbersome the management of VTE in patients with cancer by replacing parenteral with oral anticoagulation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/s-0038-1668523

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 146

Metadata

Authors
Agnelli, G., Becattini, C., Bauersachs, R., Brenner, B., Campanini, M., Cohen, A., Connors, J., Fontanella, A., Gussoni, G., Huisman, M., Lambert, C., Meyer, G., Muñoz, A., Abreu de Sousa, J., Torbicki, A., Verso, M., Vescovo, G., & for the Caravaggio Study Investigators
Venue
Thrombosis and Haemostasis
Published
2018-08-13
Volume
118
Issue
09
Pages
1668-1678
ISSN
  • 0340-6245 (ISSN-L)
  • 2567-689X
OpenAlex
W2885648944
Cited by
146
References
7
FWCI
18.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. https://app.cochat.ai/papers/10.1055/s-0038-1668523
The paper
Agnelli, G., Becattini, C., Bauersachs, R., Brenner, B., Campanini, M., Cohen, A., Connors, J., Fontanella, A., Gussoni, G., Huisman, M., Lambert, C., Meyer, G., Muñoz, A., Abreu de Sousa, J., Torbicki, A., Verso, M., Vescovo, G., & for the Caravaggio Study Investigators. (2018). Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. Thrombosis and Haemostasis. https://doi.org/10.1055/s-0038-1668523

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.